Animal & Veterinary
Beaulieu Appointed CVM Deputy Director
July 18, 1999
FDA Commissioner Jane E. Henney, M.D. has approved the appointment of Dr. Andrew J. Beaulieu as Deputy Director of FDA's Center for Veterinary Medicine (CVM) effective July 18, 1999. Dr. Beaulieu succeeds Dr. Michael J. Blackwell, who left CVM on February 1, 1999. Dr. Bert Mitchell has been Acting Deputy Director of CVM since Dr. Blackwell's departure.
After receiving his D.V.M. degree cum laude from The Ohio State University, Dr. Beaulieu came to FDA. He began his government career as a veterinary reviewer in the Office of New Animal Drug Evaluation (ONADE) in June, 1972. In 1974, Dr. Beaulieu transferred to the Office of Surveillance and Compliance, where he moved up to Division Director in the Division of Surveillance. In 1991, he became Director of the Division of Therapeutic Drugs for Food Animals in ONADE. In November, 1992, he was appointed a Deputy Director of ONADE. In addition, Dr. Beaulieu also served in the Office of Research for a brief time.
During his 27-year CVM tenure, Dr. Beaulieu has provided outstanding leadership in the direction and oversight of many of the Center's activities. CVM Director, Dr. Stephen Sundlof says, "There are few if any who command Dr. Beaulieu's historical knowledge of and broad experience within CVM. His recent efforts to re-engineer the new animal drug approval process and his experience with the implementation of the Animal Drug Availability Act (ADAA) will bring valuable perspective to his new job."
Dr. Beaulieu has received several FDA Honor Awards, including two Awards of Merit, four Commendable Service Awards, a Commissioner's Special Citation, a Deputy Commissioner's Special Recognition Award, and numerous Group Recognition Awards during his distinguished career.
Dr. Beaulieu has effectively represented the Center's interests at the national and international level. His thorough working knowledge of the animal product-related provisions, limitations and practical applications of the Food, Drug, and Cosmetic Act makes Dr. Beaulieu uniquely qualified and a valuable addition to CVM's leadership team.